While other pharmacological agents have been used to manage AD in individuals with SCI and their use has been reported in the literature (e.g. expert opinion, case report), they currently do not have sufficient evident to warrant recommendation. These include the use of Phenazopyridine for AD associated with cystitis (Paola et al. 2003), magnesium sulfate for AD associated with labour (Maehama et al. 2000) or life-threatening AD in intensive care (Jones & Jones 2002), Diazoxide (Hyperstat) (Erickson 1980) for acute AD episodes and intrathecal baclofen for AD associated with spasticity (Kofler et al. 2009). In addition, there have been reports of the use of beta blockers (Pasquina et al. 1998), Mecamylamine (Inversine) (Braddom & Rocco 1991) and Hydralzine (Apresoline) (Erickson 1980) for the general management of AD symptoms in individuals with SCI.